
Alexei Pchejetski
Mécanismes fondamentaux de la fonction du lysosome
- Professeur titulaire
-
Faculté de médecine - Département de pédiatrie
Profile
Research expertise
Lysosomal biology and lysosomal storage diseases
Lysosomes are cytoplasmic organelles harbouring over 100 hydrolytic enzymes involved in the degradation of essentially all types of biological macromolecules. Any failure in the biogenesis, lysosomal targeting, supramolecular organization or function of one or more lysosomal enzymes can result in the progressive metabolic diseases called lysosomal storage diseases because of the massive accumulation of the undegraded substrates of the deficient enzymes in the lysosomes of the affected tissues. Our research aims at discovering the genes mutated in lysosomal diseases, identifying the molecular and biochemical defects in patients and developing therapies with a special emphasis on diseases caused by the deficiencies of lysosomal sialidases (sialidosis, galactosialidosis) and N-acetyltransferases (mucopolysaccharidosis IIIC).Sialic acids and sialidases in cell signallingSialic acids are abundantly expressed on the cell surface and implicated in mediating recognition between the cells, between the cells and extracellular matrix as well as between the cells and a range of pathogenic viruses, bacteria and protozoa during the inflammatory and immune reactions. Much less is known about the role of sialidases (also called neuraminidases) and sialotransferases that can regulate cellular affinity by modifying the sialylation of cell surface molecules. Using the genetically targeted mouse models we study the role of neuraminidase 1 (Neu1) in signalling during the immune response, phagocytosis and glucose uptake, as well as the role of neuraminidase 4 (Neu4) in brain development.Serine carboxypeptidases in regulation of vasoconstriction and elastogenesisShort vasoactive peptides are recognized as potent regulators of blood circulation. Through their interaction with different cell surface receptors peptides can modulate blood pressure by such diverse mechanisms as contracting vascular smooth muscles, increasing or decreasing plasma volume, or by induction or suppression of vascular wall remodelling. Therefore proteases involved in the catabolic proteolysis of circulating vasoactive peptides, which regulates their functional longevity and availability play important role in regulation of vascular resistance. Using the knock-out mouse model we study the input of the major lysosomal serine carboxypeptidase A (cathepsin A) in post-translational processing of vasoactive peptides including angiotensin and endothelin.Functional proteomics and phosphoproteomicsPhosphorylation is the most frequent and important post-translational modification of proteins. Despite intensive research dedicated to development of methods for the analysis of a phosphoproteome, identification of low-abundant cellular phosphoproteins still remains challenging, highlighting the need for novel techniques. Our team is involved in development of new technologies for the global analysis and quantitative analysis of a phosphoproteome based on affinity resins for isolation of phosphopeptides and phosphoproteins and isotopic peptide tags. This technology should allow comparison of phosphoproteomes tracing up- and down-regulation of the individual proteins in order to identify novel drug targets and pharmacologically relevant metabolic and signaling pathways.Affiliations and responsabilities
Research affiliations
Teaching and supervision
Student supervision
Theses and dissertation supervision (Papyrus Institutional Repository)
Mucopolysaccharidosis type IIIC : molecular defects and pathophysiological mechanism
Cycle : Doctoral
Grade : Ph. D.
Neuraminidases as triggers of atherosclerosis
Cycle : Doctoral
Grade : Ph. D.
N-acétyltransférase lysosomale : organisation, fonctionnement et défauts moléculaires chez les patients atteints du syndrome de Sanfilippo type C
Cycle : Master's
Grade : M. Sc.
Lysosomal sialidase, Neu1 : the new role in cell immune response
Cycle : Doctoral
Grade : Ph. D.
Implication de la voie de dégradation ubiquitine-dépendante dans la pathologie des maladies de surchage lysosomale
Cycle : Master's
Grade : M. Sc.
Inhibition de l'apoptose par inversion du rapport [Na⁺]ᵢ/[K⁺]ᵢ : preuve de l'existence de facteur(s) de transcription sensible(s) à la [Na⁺]ᵢ et rôle de la mortaline
Cycle : Doctoral
Grade : Ph. D.
Human lysosomal sialidase : biogenesis, structure and molecular pathology in childhood inherited disorders, galactosialidosis and sialidosis
Cycle : Doctoral
Grade : Ph. D.
Identification of UDP-GicNAc phosphotransferase-binding sites on cathepsins A and D
Cycle : Master's
Grade : M. Sc.
Projects
Research projects
Neuroprotective peptides for treatment of neurological lysosomal diseases
Novel Treatments for Lysosomal Neurological Disorders: Targeting Microglia Cells and Misfolded Proteins for Therapy of Mucopolysaccharidosis IIIC
Programme de recherche pour le développement de thérapies innovantes basées sur le génie génétique des cellules et des tissus pour le traitement des maladies monogéniques et des cancers pédiatriques
Neuroprotective peptides for treatment of neurological lysosomal diseases.
Neuroprotective peptides for treatment of neurological lysosomal diseases
Neuraminidase 1 as a trigger of immune thrombocytopenia: using animal models to understand pathophysiology of the disease and develop novel therapies.
GlycoNet /Study of mucopolysaccharidosis IIIC-pertinent deficits in iPSC derived human neurons.
Exosomes as therapeutic enzyme delivery vehicles for treatment of Mucopolysaccharidosis IIIC
(GlycoNet)/Regulation of inflammatory response to bacterial infections by human neuraminidase enzymes
GlycoNet/Innovative therapies for neurological lysosomal storage disorders.
Réseau GlycoNet/Neuraminidases as a trigger of atherosclerosis.
Targeting Missfolded Proteins for Therapy of MPSIIIC
Novel Treatments for Lysosomal Neurological Disorders: Targeting Microglia Cells and Missfolded Proteins for Therapy of Mucopolysaccharidosis IIIC
Rare Diseases: Models & Mechanisms Network. Canadian "rare diseases: models & mechanisms" network (RDMM) / Réseau canadien "maladies rares : modèles et mécanismes"
Enzyme replacement therapy for Sanfilippo disease type C. Chaperone therapy for mucopolysaccharidosis IIIC (MPS IIIC). Synaptic Dysfunction in Lysosomal Storage Disorders: Pathogenic Mechanism and Potential Therapeutic Applications.
Neuraminidase 1 as a trigger of immune thrombocytopenia
Neuraminidases as a trigger of atherosclerosis.
Rare Diseases: Models & Mechanisms Network. Canadian "rare diseases: models & mechanisms" network (RDMM) / Réseau canadien "maladies rares : modèles et mécanismes"
MUCOPOLYSACCHARIDOSIS IIIC AS A PROTEIN FOLDING DISEASE : USING ANIMAL MODELS TO STUDY PATHOPHYSIOLOGY AND EXPLORE POTENTIAL THERAPEUTIC SOLUTIONS
MUCOPOLYSACCHARIDOSIS IIIC AS A PROTEIN FOLDING DISEASE: USING ANIMAL MODELS TO STUDY PATHOPHYSIOLOGY AND EXPLORE POTENTIAL THERAPEUTIC SOLUTIONS
LIPOLYSIS : BIOCHEMICAL GENETICS, PHYSIOLOGY AND MOLECULAR CIRCUITRY
SERINE CARBOXYPEPTIDASES THAT INACTIVATE SHORT VASOACTIVE PEPTIDES : ROLES IN VASOCONSTRICTION AND PROLIFERATION OF VASCULAR SMCS
IDENTIFICATION DES OLIGOSACCHARIDES D'HEPARANE SULFATES PATHOGENIQUES DANS LE SYNDROME SANFILIPPO C, MALADIE NEURODEGENERATIVE PEDIATRIQUE
SERINE CARBOXYPEPTIDASES THAT INACTIVATE SHORT VASOACTIVE PEPTIDES : ROLES IN VASOCONSTRICTION AND PROLIFERATION OF VASCULAR SMCS
IDENTIFICATION DES OLIGOSACCHARIDES D'HÉPARANE SULFATES PATHOGÉNIQUES DANS LE SYNDRÔME SANFILIPPO C, MALADIE NEURODÉGÉNÉRATIVE PÉDIATRIQUE
CARBOXYPEPTIDASES THAT INACTIVE SHORT VASOACTIVE PEPTIDES: ROLES IN VASOCONSTRICTION AND PROLIFERATION OF VASCULAR SMCS
Areas of expertise
- Nucleic Acids
- Blood Flow and Transfusions
- Enzymes and Proteins
- Functional and Structural Proteomics
- Immune Reactions
- Cell Signaling (Circulatory and Respiratory Health)